A detailed history of Gsa Capital Partners LLP transactions in Aquestive Therapeutics, Inc. stock. As of the latest transaction made, Gsa Capital Partners LLP holds 137,151 shares of AQST stock, worth $423,796. This represents 0.05% of its overall portfolio holdings.

Number of Shares
137,151
Previous 21,928 525.46%
Holding current value
$423,796
Previous $57,000 1098.25%
% of portfolio
0.05%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 05, 2024

BUY
$2.4 - $5.09 $276,535 - $586,485
115,223 Added 525.46%
137,151 $683,000
Q2 2024

Aug 15, 2024

BUY
$2.31 - $4.5 $50,653 - $98,676
21,928 New
21,928 $57,000
Q3 2023

Nov 15, 2023

BUY
$1.5 - $2.24 $130,353 - $194,660
86,902 Added 622.86%
100,854 $154,000
Q2 2023

Aug 14, 2023

BUY
$1.06 - $2.49 $14,789 - $34,740
13,952 New
13,952 $23,000
Q3 2022

Nov 14, 2022

BUY
$0.63 - $1.73 $8,633 - $23,707
13,704 New
13,704 $16,000
Q2 2022

Aug 09, 2022

SELL
$0.64 - $2.57 $22,252 - $89,356
-34,769 Closed
0 $0
Q1 2022

May 11, 2022

SELL
$2.28 - $4.26 $143,715 - $268,520
-63,033 Reduced 64.45%
34,769 $91,000
Q4 2021

Feb 14, 2022

SELL
$3.69 - $6.37 $735,885 - $1.27 Million
-199,427 Reduced 67.1%
97,802 $380,000
Q3 2021

Nov 12, 2021

BUY
$3.25 - $4.66 $648,141 - $929,334
199,428 Added 203.91%
297,229 $1.3 Million
Q2 2021

Aug 05, 2021

SELL
$3.29 - $5.21 $361,268 - $572,099
-109,808 Reduced 52.89%
97,801 $388,000
Q1 2021

May 10, 2021

BUY
$4.17 - $6.73 $865,729 - $1.4 Million
207,609 New
207,609 $1.08 Million
Q2 2019

Aug 06, 2019

SELL
$3.72 - $6.95 $42,408 - $79,230
-11,400 Closed
0 $0
Q1 2019

May 15, 2019

BUY
$5.74 - $8.05 $65,436 - $91,770
11,400 New
11,400 $79,000

Others Institutions Holding AQST

About Aquestive Therapeutics, Inc.


  • Ticker AQST
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 53,350,700
  • Market Cap $165M
  • Description
  • Aquestive Therapeutics, Inc., a pharmaceutical company, focuses on identifying, developing, and commercializing various products to address unmet medical needs in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual f...
More about AQST
Track This Portfolio

Track Gsa Capital Partners LLP Portfolio

Follow Gsa Capital Partners LLP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Gsa Capital Partners LLP, based on Form 13F filings with the SEC.

News

Stay updated on Gsa Capital Partners LLP with notifications on news.